Eli Lilly opens a USD6B Orforglipron facility in Alabama

 USA—American pharmaceutical giant Eli Lilly has chosen Huntsville, Alabama, as the site for its third manufacturing plant dedicated to orforglipron, a promising oral treatment candidate in its obesity and type 2 diabetes portfolio.

The new USD6 billion facility is expected to break ground in 2026, marking a major step in Lilly’s broader U.S. expansion strategy.

Once construction begins, the project will generate approximately 3,000 construction-related roles, providing a significant economic boost to the local community.

When fully operational, the facility will offer more than 450 high-skilled positions, including opportunities for engineers, scientists, operations experts, and lab technicians.

 At this site, Lilly will produce both small-molecule synthetic and peptide-based medicines, including orforglipron—anticipated to become a key addition to the company’s glucagon-like peptide-1 receptor agonist (GLP-1RA) therapies.

To deliver efficient and secure manufacturing operations, Eli Lilly plans to integrate machine learning (ML), artificial intelligence (AI), and digital automation into the plant’s systems.

These technologies will streamline processes, strengthen supply chains, and enhance overall productivity.

The move builds on Lilly’s growing adoption of advanced computing innovations.

Earlier this year, the company collaborated with NVIDIA to create what it described as its most powerful supercomputer to accelerate the pace of drug discovery and design.

The Alabama site is part of Lilly’s USD 27 billion U.S. onshoring initiative, aimed at reinforcing domestic pharmaceutical manufacturing.

As part of this nationwide plan, the company intends to build four new facilities, including a USD6.5 billion orforglipron manufacturing site in Texas and a USD5 billion complex in Virginia dedicated to bioconjugate and monoclonal antibody (mAb) production.

Additionally, Lilly will invest USD 1.2 billion to expand its existing orforglipron plant in Puerto Rico, further strengthening its production pipeline across the Americas.

Industry analysts suggest that the company’s rapid scale-up is influenced in part by proposed trade measures under the Trump administration, which has warned of imposing 100% tariffs on branded pharmaceuticals unless companies expand their manufacturing presence in the United States.

Although such tariffs have not yet taken effect, major market players like Eli Lilly appear to be moving quickly to fortify their domestic operations.

Beyond the U.S., Lilly is also increasing its European manufacturing capacity.

It has announced plans to construct a new USD3 billion orforglipron facility in the Netherlands and expand its Limerick, Ireland, site through a USD1 billion investment.

This international buildout reflects the company’s global growth ambitions, driven largely by surging demand for obesity and type 2 diabetes treatments, including its top-selling products Zepbound and Mounjaro (tirzepatide).

Following its entry into the USD 1 trillion market capitalization tier, Eli Lilly is preparing to submit a new drug application (NDA) for orforglipron to the U.S. Food and Drug Administration (FDA).

According to forecasts from GlobalData, the drug could generate USD13 billion in annual sales by 2031, with an expected commercial launch in 2026.

However, Lilly faces strong competition from Novo Nordisk, whose oral Wegovy (semaglutide)—another GLP-1RA candidate—is currently under FDA review, with a regulatory decision anticipated in late 2025.